Abbott Laboratories Pakistan Limited · PSX:ABOT
Abbott Laboratories Pakistan — Investor Presentation (December 2024)
19 slides from Abbott Laboratories Pakistan's investor presentation, Dec 17, 2024
Slide 1: Corporate Briefing Session - 2024
Corporate Briefing Session - 2024 December 17th, 2024
Slide 2: Table of Contents
Table of Contents • Company Overview • Economic Overview • Strategic / Operational Developments • Financial Results for 2023 • Financial Results for Q3-2024 • Q&A
Slide 3: Company Overview
Company Overview Incorporated on July 02, 1948 1962 – Set up Other segments manufacturing Two manufacturing (mainly includes facility in Karachi general health and and listed as public facilities diabetes care) limited company in 1982 Abbott Laboratories (Pakistan) Limited 1,430 Employees Diagnostic
Slide 4: Pakistan – Macro Economic Overview
PAKISTAN – MACRO ECONOMIC OVERVIEW Gross Domestic Product Growth (GDP%) Growth of Pakistan: 8% • GDP growth FY24 - posted a growth of 2.38% in 7% FY2024 against target of 5%. The prudent policy 6.10% 6.10% 5.77% management and the resumption of inflows from 6% 4.56% 4.61% Target multilateral and bil
Slide 5: Fiscal Landscape
FISCAL LANDSCAPE FBR REVENUE COLLECTION Rs bln Rs. Billion 5,000 • FBR revenue collection: During Jul-Sep FY2025, the net 4,019 4,000 federal revenues grew by 186 percent to Rs 4,019 billion from 3,000 2,438 2,483 Rs 1,406 billion same period last year. This was on account of 2,000 1,406 various mea
Slide 6: Monetary Landscape & Currency Outlook
MONETARY LANDSCAPE & CURRENCY OUTLOOK CPI & POLICY RATE TREND CPI & POLICY RATE TREND • Expansionary Monetary policy: Central bank has brought down 36.00% the interest rate to 15% from an unprecedented 22% in four 32.00% intervals since June. 28.00% 24.00% • Policy rate: Expected to reduced by 200bp
Slide 7: Strategic / Operational Developments: Deregulation of Non-Essential Drugs
STRATEGIC / OPERATIONAL DEVELOPMENTS Deregulation of Non-Essential Drugs ❑ During the year, Government of Pakistan approved De-Regulation of drug prices which are not included in National Essential Medicine List (NEML). ❑ In view of this development, the industry took price increases on its non-esse
Slide 8: Financial Results - 2023
Financial Results - 2023
Slide 9: Key Highlights – FY2023
Key Highlights – FY2023 • Overall revenue of the Company increased by 13% reaching Rs. 55.48 bn. Rs. 55.48 bn 13% Sales Revenue Sales Growth • Decrease in profitability mainly on account of increase in product cost and rupee devaluation. • Earnings per share was Rs. 2.67 per share (2022: Rs. 30.69 p
Slide 10: Revenue Analysis – FY23
Revenue Analysis – FY23 Annual revenue 56,000 55,475 55,000 Segment wise Revenue 54,000 13% 53,000 (PKR in millions) PKR in millions 52,000 51,000 50,000 49,258 Segment 2023 2022 % Change 49,000 48,000 47,000 Pharmaceutical 37,783 31,486 20% 46,000 2022 2023 Nutritional 11,414 12,365 -8% ➢ Pharmaceu
Slide 11: Segment Gross Profit analysis – FY23
Segment Gross Profit analysis – FY23 Segment GP 16,000 Segment-wise GP (PKR in millions) 14,526 (8%) 14,000 11,848 12,000 Segment 2023 GP % 2022 GP % PKR in millions 10,000 8,000 6,000 Pharmaceutical 7,955 21% 9,336 30% 4,000 2,000 - Nutritional 2,726 24% 4,488 36% 2022 2023 ➢ Segment profitability
Slide 12: Financial Results – Q3 2024
Financial Results – Q3 2024
Slide 13: Key Highlights – Q3 2024
Key Highlights – Q3 2024 • Overall revenue of the Company increased by 20% reaching Rs. 49.56 bn. Rs. 49.56bn 20% • Profitability improved Sales Revenue Sales Growth significantly following price adjustment and various other efficiency measure taken across the operations. 28% 8% Gross Profit Net Pro
Slide 14: Revenue Analysis – Q3 2024
Revenue Analysis – Q3 2024 50,000 Revenue Segment wise Revenue 45,000 40,000 20% (PKR in millions) Jan - Sep Jan - Sep 49,564 35,000 Segment % Inc 30,000 41,225 2024 2023 25,000 PKR in 20,000 15,000 Pharmaceutical 33,469 27,417 22% 10,000 5,000 0 Nutritional 10,129 8,975 13% Q3 2023 Q3 2024 ➢ Pharma
Slide 15: Segment Gross Profit analysis – Q3 2024
Segment Gross Profit analysis – Q3 2024 Segment GP 16,000 14,101 Segment-wise GP (PKR in millions) 14,000 12,000 PKR in million Jan - Sep Jan - Sep Segment 2024 GP % 2023 GP % 10,000 8,315 8,000 6,000 Pharmaceutical 9,615 29% 5,743 21% 4,000 2,000 Nutritional 3,544 35% 2,011 22% Q3 2023 Q3 2024 ➢ Ov
Slide 16: Statement of Profit or Loss – Q3 2024
Statement of Profit or Loss – Q3 2024 Variance – Fav / Description % Jan - Sep 2024 % Jan - Sep 2023 (Unfav) Rupees in millions % Sales 100 49,564 100 41,225 8,339 20 Cost of Sales 72 35,463 80 32,910 2,553 8 Gross Profit 28 14,101 20 8,315 5,786 70 Selling and Distribution expenses 14 7,120 15 6,19
Slide 17: Statement of Financial Position – Sep 30, 2024
Statement of Financial Position – Sep 30, 2024 Dec Sep Dec Description Sep 2024 Variance Description Variance 2023 2024 2023 Rupees in Millions % Rupees in Millions % Non-current assets Share capital and reserves Property, plant and equipment 13,926 13,375 551 4 Issued, subscribed and paid-up capita
Slide 18: Q&A
Q&A
Slide 19: Thank you
Thank you
Abbott Laboratories (Pakistan) — Investor Presentation (December 2024) on 6ix